Cedazuridine (WHO-10741; E-7727), a cytidine deaminase inhibitor, is one of the components in the anticancer drug combination: Decitabine/cedazuridine which is a marketed drug sold under the trade name of Inqovi, a fixed-dose combination medication approved in 2020 for the treatment of MDS/myelodysplastic syndromes and chronic myelomonocytic leukemia. Decitabine is a nucleoside metabolic inhibitor, and cedazuridine is a cytidine deaminase inhibitor.

纯度：≥98%

CAS：1141397-80-9